Ekso Bionics(US:EKSO)2025-10-28 20:05Financial Performance - Revenue for Q3 2025 was $4.2 million, a 2% increase year-over-year and a 105% sequential increase from Q2 2025[3] - Gross profit for Q3 2025 was $2.5 million, with a gross margin of approximately 60.3%, up from 53.5% in Q3 2024[4] - Net loss for Q3 2025 improved by 31% year-over-year to $1.4 million, or $0.54 per share, compared to a net loss of $2.1 million, or $1.53 per share, in Q3 2024[7] Expenses - Sales and marketing expenses decreased to $1.3 million in Q3 2025 from $1.8 million in Q3 2024, primarily due to lower payroll expenses[5] - Research and development expenses for Q3 2025 were $0.6 million, down from $0.8 million in Q3 2024[6] Strategic Initiatives - The company launched eksoUniversity and delivered its first official CEU certification to a physical therapist in Connecticut[9] - The company is exploring strategic transactions, which may include acquisitions or the sale of its current business[10] Cash and Assets - As of September 30, 2025, the company had cash of $2.7 million, down from $4.5 million at the end of 2024[8] - Total current assets decreased to $14.8 million as of September 30, 2025, from $18.8 million at the end of 2024[15] - Total liabilities as of September 30, 2025, were $12.0 million, down from $13.9 million at the end of 2024[15]